Increase in lifestyle-related cancers over past decade spotlights need for prevention

June 02, 2018

SEATTLE - Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

"While the increase in lung, colorectal, and skin cancers over the past decade is concerning, the prevention potential is substantial," said Dr. Christina Fitzmaurice, Assistant Professor of Global Health at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, whose organization coordinated the study. "Vital prevention efforts such as tobacco control, dietary interventions, and broader health promotion campaigns need to be scaled up in response to this rise in lifestyle-related cancers."

The study, published today in JAMA Oncology, covers 1990 to 2016; it is part of the Global Burden of Disease (GBD) study, a comprehensive effort to quantify health internationally. Researchers reviewed 29 cancer groups, including lung, breast, prostate, skin, colorectal, pancreatic, stomach, and liver cancers, as well as leukemia and other cancer groups (full list below). The study provides findings by age and sex for 195 countries and territories.

While lifestyle-related cancers saw a universal increase from 2006 to 2016, several cancers from infectious causes - including cervical and stomach cancers - decreased over the same time period.

Study estimates were analyzed using a Socio-demographic Index (SDI) based on rates of education, fertility, and income. SDI is more comprehensive than the historical "developed" versus "developing" nations framework. Countries with high SDI have high levels of income and education and low fertility, whereas low-SDI countries have low levels of income and education and high fertility.

Large disparities in cancer incidence and death persist between high- and low-SDI countries. Researchers found rates of cancer incidence and death remained higher in high-SDI countries in 2016. For example, the odds of developing breast cancer over the course of one's lifetime were the highest - at 1 in 10 women - in high-SDI countries, but only 1 in 50 for women in low-SDI countries.

Conversely, the largest and fastest increase in new cancer cases between 2006 and 2016 occurred in middle-SDI countries. And women in low-SDI countries are nearly four times more likely to develop cervical cancer than women in high-SDI countries, and in 2016, cervical cancer was the most common cause of cancer incidence and death in low-SDI countries.

"Ensuring universal access to health care is a vital prerequisite for early detection and cancer treatment," said Fitzmaurice. "And improving access to advanced diagnostic technologies not commonly available in low-SDI countries is a critical step toward achieving health equity globally."

Additional key findings include: NEW CASES PER 100,000 PEOPLE (AGE-ADJUSTED), 2016
"Worst" and "best" countries and global

  1. Tracheal, bronchus, and lung cancer: North Korea (56.9), Kenya (4.2), global (30.2)
  2. Colon and rectum cancer: Netherlands (57.5), The Gambia (4.3), global (25.9)
  3. Breast cancer: Luxembourg (61.8), Niger (5.8), global (24.1)
  4. Non-melanoma skin cancer: Australia (300.4), Bangladesh (0.7), global (23.2)
  5. Prostate cancer: Dominica (113.1), North Korea (2.4), global (22.1)
  6. Stomach cancer: South Korea (44.5), Namibia (2.7), global (17.3)
  7. Liver cancer: Mongolia (108.4), Morocco (1.9), global (14.6)
  8. Other neoplasms: Malawi (39.6), Syria (2.6), global (10.9)
  9. Cervical cancer: Somalia (34.0), Qatar (1.1), global (7.0)
  10. Leukemia: New Zealand (20.3), Zambia (2.0), global (6.8)
  11. Non-Hodgkin lymphoma: Canada (21.2), Kyrgyzstan (1.5), global (6.7)
  12. Bladder cancer: Lebanon (31.1), Nigeria (1.2), global (6.7)
  13. Esophageal cancer: Malawi (25.2), Syria (0.7), global (6.6)
  14. Pancreatic cancer: Czech Republic (12.5), India (2.6), global (6.4)
  15. Uterine cancer: Latvia (23.1), Bangladesh (0.8), global (6.0)
  16. Lip and oral cavity cancer: Pakistan (22.1), Sao Tome and Principe (1.0), global (5.5)
  17. Kidney cancer: Latvia (20.5), Nepal (1.0), global (5.0)
  18. Brain and nervous system cancer: Iceland (20.8), Namibia (1.4), global (4.6)
  19. Malignant skin melanoma: Australia (55.6), Nepal (0.2), global (4.1)
  20. Ovarian cancer: Estonia (9.3), Niger (1.2), global (3.6)
  21. Thyroid cancer: Iceland (18.7), Ghana (0.2), global (3.3)
  22. Gallbladder and biliary tract cancer: Chile (11.5), Uzbekistan (0.6), global (2.8)
  23. Larynx cancer: Cuba (8.8), The Gambia (0.6), global (2.7)
  24. Other pharynx cancer: Hungary (7.3), Palestine (0.2), global (2.4)
  25. Multiple myeloma: Barbados (6.3), Tajikistan (0.4), global (2.1)
  26. Nasopharynx cancer: Malaysia (5.1), Mali (0.1), global (1.3)
  27. Hodgkin lymphoma: Greece (5.3), Syria (0.1), global (1.0)
  28. Testicular cancer: Chile (6.4), Mozambique (0.04), global (0.9)
  29. Mesothelioma: United Kingdom (2.9), Palestine (0.1), global (0.5)

"Worst," and "best" countries and global

  1. Tracheal, bronchus, and lung cancer: North Korea (61.7), Egypt (4.8), global (25.8)
  2. Colon and rectum cancer: Hungary (31.3), Sri Lanka (5.0), global (12.8)
  3. Stomach cancer: Mongolia (44.0), Maldives (3.2), global (12.6)
  4. Liver cancer: Mongolia (114.7), Morocco (2.0), global (12.1)
  5. Breast cancer: Tonga (24.7), Oman (4.0), global (7.9)
  6. Other neoplasms: Malawi (37.6), Syria (2.6), global (6.4)
  7. Esophageal cancer: Malawi (32.4), Syria (0.8), global (6.2)
  8. Pancreatic cancer: Uruguay (12.8), Bangladesh (2.5), global (6.2)
  9. Prostate cancer: Dominica (54.9), North Korea (1.9), global (6.1)
  10. Leukemia: Syria (15.3), Bangladesh (1.9), global (4.6)
  11. Non-Hodgkin lymphoma: Grenada (11.0), Kyrgyzstan (1.4), global (3.6)
  12. Cervical cancer: Zimbabwe (28.7), Syria (0.6), global (3.5)
  13. Brain and nervous system cancer: Palestine (8.3), Japan (1.2), global (3.2)
  14. Bladder cancer: Malawi (11.8), Albania (0.9), global (2.9)
  15. Lip oral cavity cancer: Kiribati (14.6), Syria (0.6), global (2.6)
  16. Gallbladder and biliary tract cancer: Chile (11.3), Uzbekistan (0.6), global (2.5)
  17. Ovarian cancer: Lithuania (5.9), United Arab Emirates (0.9), global (2.4)
  18. Kidney cancer: Czech Republic (7.1), Bangladesh (0.5), global (2.0)
  19. Other pharynx cancer: India (6.1), Syria (0.2), global (1.7)
  20. Larynx cancer: Cuba (5.3), Japan (0.4), global (1.6)
  21. Multiple myeloma: Dominica (5.9), Tajikistan (0.4), global (1.5)
  22. Uterine cancer: Grenada (5.4), Maldives (0.5), global (1.3)
  23. Malignant skin melanoma: New Zealand (6.6), Bangladesh (0.2), global (0.9)
  24. Nasopharynx cancer: Malaysia (3.7), Chile (0.1), global (0.9)
  25. Non-melanoma skin cancer: Zimbabwe (4.5), Bangladesh (0.2) global (0.8)
  26. Thyroid cancer: Zimbabwe (2.3), Syria (0.2), global (0.6)
  27. Mesothelioma: United Kingdom (2.6), Palestine (0.1), global (0.5)
  28. Hodgkin lymphoma: Afghanistan (2.2), Japan (0.1), global (0.4)
  29. Testicular cancer: Kiribati (1.0), Maldives (0.02), global (0.1)


Highest rates

  1. Australia (743.8)
  2. New Zealand (542.8)
  3. United States (532.9)
  4. Netherlands (477.3)
  5. Luxembourg (455.4)
  6. Iceland (455.0)
  7. Norway (446.1)
  8. United Kingdom (438.6)
  9. Ireland (429.7)
  10. Denmark (421.7)

Lowest rates

  1. Syria (85.0)
  2. Bhutan (86.0)
  3. Algeria (86.7)
  4. Nepal (90.7)
  5. Oman (94.9)
  6. Maldives (101.3)
  7. Sri Lanka (101.6)
  8. Niger (102.3)
  9. Timor-Leste (105.9)
  10. India (106.6)


Highest rates

  1. Mongolia (272.1)
  2. Zimbabwe (245.8)
  3. Dominica (203.1)
  4. Hungary (202.7)
  5. Grenada (201.0)
  6. Uruguay (190.6)
  7. Tonga (189.7)
  8. North Korea (188.7)
  9. Saint Vincent and the Grenadines (183.1)
  10. Croatia (180.2)

Lowest rates

  1. Syria (67.4)
  2. Algeria (67.5)
  3. Oman (69.2)
  4. Maldives (72.0)
  5. Sri Lanka (74.7)
  6. Bhutan (78.6)
  7. Uzbekistan (80.6)
  8. Nicaragua (80.9)
  9. Morocco (81.0)
  10. Qatar (81.6)
The study, "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016," was published today in JAMA Oncology.

Media contacts:

IHME: Kelly Bienhoff, +1-206-897-2884 (office); +1-913-302-3817 (mobile);

IHME: Dean Owen, +1-206-897-2858 (office); +1-206-434-5630 (mobile);

JAMA Network Media Relations, +1-312-464-JAMA (5262);

About the Institute for Health Metrics and Evaluation

The Institute for Health Metrics and Evaluation (IHME) is an independent global health research organization at the University of Washington that provides rigorous and comparable measurement of the world's most important health problems and evaluates the strategies used to address them. IHME makes this information widely available so that policymakers have the evidence they need to make informed decisions about how to allocate resources to improve population health.

Institute for Health Metrics and Evaluation

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to